The Link between Gut Microbiota and Hepatic Encephalopathy

Area of Science:

• Gastroenterology and Hepatology
• Neuroscience
• Microbiology

Background:

• Hepatic encephalopathy (HE) is a severe complication of cirrhosis, manifesting as neuropsychiatric issues like cognitive decline and movement disorders.
• The gut-liver-brain axis, significantly influenced by the gut microbiome, is central to HE pathogenesis.
• Current HE treatments targeting the gut microbiota have limitations.

Purpose of the Study:

• To review factors impacting the gut-liver-brain axis in cirrhosis-related HE.
• To explore the relationship between these factors and the gut microbiome.
• To evaluate clinical studies on microbiome-targeted therapies for HE management.

Main Methods:

• Narrative review of existing literature.
• Identification of factors negatively influencing the gut-liver-brain axis.
• Evaluation of clinical studies on microbiome-modulating treatments for HE.

Main Results:

• The gut microbiome plays a critical role in HE development and progression.
• Microbiome-targeted interventions like probiotics, prebiotics, fecal microbiota transplantation (FMT), and antibiotics (e.g., rifaximin) show potential in managing HE.
• These therapies aim to correct gut dysbiosis, reduce harmful bacteria, and improve cognitive function and hyperammonemia.

Conclusions:

• Microbiome-targeted therapies offer a promising avenue for HE treatment, with strategies including probiotics, prebiotics, FMT, and specific antibiotics.
• Despite successes, current treatments face limitations, highlighting the need for personalized therapeutic designs.
• Future research should focus on tailored approaches to optimize HE management through gut microbiome modulation.